newsfilter
← Latest News
PR Newswire·

Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th

Phio's INTASYL™ compounds demonstrated activity against multiple protein targets including PD-1, BRD4, CTLA-4, TIGIT and CTGF. INTASYL™ compounds demonstrated preclinical activity in both